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examination of 2 patients revealed PCR positivity with a 3 or 4- 
log increases of normalized BCR-ABL amount and subsequent 
hematologic relapse, which occurred 2 and 4 months later, respec- 
tively. Although our data should be interpreted cautiously, the 
presence of chronic GVHD may reduce the risk of relapse in Ph+ 
ALL. Real-time quantitative RT-PCR appears to be a useful test 
for BCR-ABL transcript monitoring. 
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ALLOGRAFTING WITH FLUDARABINE AND ATG AFTER FAILED 
ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS 
Bayer, R.; Focazio, B.; Johl~, V.; Loscalz~o, ft.; Buchbi~der, A. North 
Shore UlTiversity Hospital, Ma~hasset, NK 
High-dose myeloablative r gimens with autologous stem cell 
transplantation have been pursued as a consolidation strategy in 
first remission AML patients. We report two patients with AML 
who received autologous tem cell transplants in first CR. Both 
patients received similar regimens and failed to engraft heir 
autologous blood stem cells. Both were then given Fludarabine 
and ATG with subsequent engraftment of cells from an HLA 
matched sibling. Patient A.S. is a 32 y.o male diagnosed with 
AML, FAB subtype M2, with normal cytogenetics who received 
induction chemotherapy with Ara-C 100mg/m2 x7 days, 
Daunorubicin 40mg/m2 x3 and VP16 40mg/m2 x3. His intensifi- 
cation/mobil ization i cluded Ara-C 2gin/m2 x8 and VPI6 
10mg/kg x4. The regimen used for autologous stem cell transplant 
was Busulfan p.o. lmg/kg x16 doses and VP16 60mg/kg xl. He 
received 15.6 x 10 E6 CD34 cells/kg bodyweight. On day 52 there 
was no sign of engraftment. He was then given Fludarabine 
30mg/m2 x4 doses and ATG 15mg/kg x6 doses. Peripheral blood 
stem cells, 4.2 x 10 E6 CD34 cells/kg, were given from his HLA 
matched brother. Engraftment was noted on Day 12 post trans- 
plant. He had no signs of GVHD. He is now 100% donor, con- 
firmed by variable number tandem repeats (VNTR). Patient R.S. 
is a 46 y.o male who was diagnosed with AML, FAB subtype M2, 
with normal cytogenetics. His induction chemotherapy consisted 
ofAra-C 100mg/m2 x7 days and Daunorubicin 30rag/m2 x3 days. 
This was followed by an intensification/mobilization regimen of 
Ara-C 2gm/m2 x8 doses and VP16 10mg/kg x4 doses. He received 
Busulfan 1V 0.8mg/kg x16 doses and VP16 60mg/kg xl dose as a 
regimen for his autologous stem cell transplant. He received 11 x 
10 E6 CD34 cells/kg bodyweight. On day 36 there was no 
engraftment. He was then given Fludarabine 30rag/m2 x4 doses 
and ATG 15mg/kg x6 doses. He was given peripheral blood stem 
cells, 2.1 x 10 E6 CD34 cells, from his HLA matched brother. 
Engraftment was noted on Day 7 post transplant. The patient 
developed Grade I GVHD which responded to treatment with 
Prednisone. He is presently 98% donor confirmed by VNTR. We 
conclude that Fludarabine and Antithymocyte globulin is a safe 
and effective regimen for allografting after failed engraftment of
autologous peripheral blood stem cells in patients with AML. 
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THE CD4 PEPTIDE ANALOGUE 802-2 INHIBITS PROLIFERATION 
OF BOTH THI AND TH2 CELLS IN RESPONSE TO ALLOGENEIC 
STIMULATION 
Zbu, Z.; Mooketjee, B.; Ko~zgold, R.; Flome~berg, N. Tbomas Jeffer- 
so~ University School of Medich~e, Philadelphia, PA. 
Engagement of CD4 and the T cell ?eceptor (TCR)-CD3 com- 
plex generates signals which lead, in part, to the activation of 
helper T (Th) cells. Activated Th cells contribute to graft-versus- 
host disease (GVHD) arising from allogeneic MHC class II and 
minor histocompatibility antigenic differences. The 802-2 syn- 
thetic cyclic heptapeptide, designed and confirmed by NMR spec- 
troscopy to mimic the D1-CC' loop of CD4, inhibits Th cell acti- 
vation in human and murine systems. Since Th l  cells appear to be 
more important in the pathogenesis of acute GVHD than their 
Th2 counterparts, the efficacy of 802-2 in modulating allogeneic 
responses of both Th l  and Th2 cells was therefore tested. Prima- 
i T polarization of Th cells was performed by stimulating purified 
CD4+ cells from healthy donors with irradiated EBV transformed 
B cells (EBV-B) obtained from unrelated, HLA ntismatched 
donors in the presence ofTh l  (IL-2 + IL-12) or Th2 (IL-2 + IL- 
4) polarizing cytokines. After similar restimulation on days 3 and 
6, cells were subsequently propagated in the presence irradiated 
autologous mononuclear cells through weekly allogeneic restimn- 
lation and biweekly cytokine supplementation. Th l  and Th2 cells 
from 3-4 week old cultures were harvested and stimulated with 
irradiated EBV-B in the presence of IL-2 with and without 802-2 
peptide. The presence of 802-2 (200gM) reduced the proliferation 
of both Thl  and Th2 cells to near background levels. Delaying 
exposure to 802-2 by more than 72 hours after allogeneic stimula- 
tion substantially reduced or eliminated its ability to inhibit prolif- 
eration. While murine Th cells, activated in vivo, in the presence 
of 802-2 appear to undergo apoptosis, it has not been possible to 
similarly demonstrate apoptosis of human Th cells activated in 
vitro in the presence of 802-2. The lack of inhibitory effects of 
802-2 when added at later time points after allostimulation rules 
out a non-specific inhibition of cellular proliferation or toxicity. 
We hypothesize that 802-2 inhibits multimerization of the 
CD4/MHC class-II/antigen/TCR complex during allostinmla- 
tion. The resultant spatial disruption of the associated signaling 
molecules leads to abrogation of the signals for cell proliferation 
and may render the Th cells anergic, as occurs in other situations 
where lymphocytes receive partial or disordered activation signals. 
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ADDING MYCOPHENOLATE MOFETIL (MMF) AND ATGAM TO 
CYCLOSPORIN DECREASES SEVERE GVHD AND TRANSPLANT-RELAT- 
ED MORTALITY (TRM) AFTER NON-MYELOABLATIVE ALLOGENEIC 
PBSC TRANSPLANTATION (MINI-PBSCT) 
SchwareT; A.P.; Spe~ce~, A.; Kapusc#~ski, M.; ~/btirhead, ,7.Boise Mar- 
row Tra~lsplantatio~, Alfi'ed Hospital, Melbou~n~e, 7C, Amtralia. 
INTRODUCTION:  Mini-PBSCT can provide cure for some 
older or less fit patients with hematological malignancies not eligi- 
ble for standard PBSCT. Mini-PBSCT uses lower doses of condi- 
tioning chemotherapy and/or radiotherapy to improve the safety 
of allogeneic PBSCT and relies on the graft-versus-tumor (GVT) 
effect for cure. METHODS: We treated 31 patients, not eligible 
for standard PBSCT, with mini-PBSCT: median age 51 (29-63) 
yrs; 20 male, 11 female; 25 advanced isease (6 AML)CR1, 5 
NHL, 4 myeloma, 2 MDS, 2 HD, 2 mycosis fungoides, and 1 
each of CML-BC, YValdenstom's macroglobulinemia, myelofibro- 
sis, T-PLL) and 6 early disease (2 AML-CR1, 2 CLL, l CML, 1 
LG-NHL). All patients received fludarabine (25 mg/m 2 x5) and 
melphalan 140 mg/rn 2prior to undergoing HLA-matched (22 sib- 
ling, 1 cousin, 8 unrelated) donor mini-PBSCT. The first 12 
patients received CSA 3 mg/m2/day M alone as GVHD prophy- 
laxis in an attempt o not excessively inhibit a potential GVT 
effect. An unacceptably high incidence of severe acute GVHD and 
TRM occurred with a low relapse rate. Therefore, we modified 
the protocol to include ATGAM 15 mg/kg from day 4 to +5 and 
MMF 15 mg/m 2 from day 0 to +27 for all subsequent patients 
(n=19). RESULTS:  Although more patients in 
CSA/ATGANUMMF cohort than CSA alone cohort underwent 
mini-PBSCT with unrelated onors (42% vs 0%) the incidence of
severe acute and extensive chronic GVHD was less, 100 day TRM 
was less (see Table) and overall TRM was less (26% vs 42%; 
p=0.38) in CSA/ATGAM/MMF cohort. To date, the relapse rate 
was similar in both cohorts although the follow-up of survivors 
was shorter in CSA/ATGAMJMMF cohort - 504 (19-634) days vs 
942 (865-1089) days. CHIMERISM:  T cell and myeloid 
chimerism using VNTR polymorphism analysis was assessed in 
CSA/ATGAM/MMF cohort but not the earlier CSA alone 
cohort. Of 14 evaluable patients 13 showed sustained >90-95% 
donor chinaerism by 1 month post mini-PBSCT. The remaining 
patient achieved <50% donor chimerism which was managed by 
ceasing MMF; >90% donor chimerism rapidly developed accom- 
panied by the onset of severe acute GVHD. No graft rejection 
was noted in either cohort. CONCLUSION: The combination 
of CSA/ATGAM/MMF appears to be effective GVHD prophy- 
laxis for older, less fit patients with advanced isease undergoing 
mini-PBSCT. 
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CSA alone (n=12) CSA/ATGAM/MMF p 
acute GVHD (grade C D) i 67% 29% ] 0.07 
chronic GVHD (extensive) 78% 57% ] 040  
i 
i 
TRM (day 100) 33% 16% i 0.38 
Re lapse 25 % 21 c/~, ~ 1  0 
Alive 42% 58% ~0738 / 
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THROMBOTIC THROMBOCYTOPENIC PURPURA FOLLOWING BONE 
MARROW TRANSPLANT TREATMENT AND OUTCOME IN TEN 
PATIENTS 
Peres, E.M.; Abella, E.; Damey, R. Stem cell Tmmplam, K~Trmanos 
Cancer Institute, Detroit, MI. 
Severe thrombotic thrombocytopenic purpura OH'P) requiring 
intervention is a serious complication following bone marrow 
transplant (BMT). The therapeutic modalities (unlike classic T IP )  
are limited since therapeutic plasma exchange has a very poor 
response. BMT TTP is usually associated with cyclosporine, total 
body irradiation or other medications. A total of 10 patients who 
underwent BNIT were diagnosed with severe TTP  during 1996- 
2001 age range 5-58 (mean 27.2). The diagnosis was made based on 
the criteria of thrombocytopenia, microhemangiopathic emolytic 
anemia, elevated LDH mean 5012 (range 4672-9232) and schisto- 
cytes on the peripheral smear. Of the 10 patients, 2 were treated 
with plasma exchange (20%), and 9 patients were treated with sup- 
portive care and the discontinuation f cyclosporine (90%). Of the 
10 patients 9 were allogeneic bone marrow transplants 5 being 
MUD (50%) all patients except i were receiving cyclosporine at 
the time of diagnosis. Outcome: mortality was 100% in all patients 
treated with and without plasma exchange. There appears to be no 
benefit of plasma exchange in patients with severe TTP  after BMT 
and an improved understanding of the pathogens i and treatment 
of this complication is currently needed. 
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A FLUORESCENCE-BASED ASSAY SUITABLE FOR MONITORING NR 
ACTIVITY IN CLINICAL SETTINGS 
Sto~wls, R. V~I; Gree~z, P.D/; Chao, N.J/; Smitt,, C,4.2; Nikcevieh, 
D.AJ 1. Departmem of Medicim, Dzdee U~tiversity 3ledical Cemer, 
Din'ham,, NC; 2. Moffitt Cmzcer Cemer, Tampa, FL. 
Natural killer (NK) cells are increasing important within the con- 
text of cellular therapies, to include allogeneic bone marrow trans- 
plantafion and donor lymphocyte infilsions. Historically, 51Cr release 
has been the standard hz vitro measurement for NK activity. Howev- 
er, qCr release has pour sensitivity for NK activity if effector cell 
numbers are limiting and patients undergoing allogeneic transplanta- 
tion frequently have very low blood cell counts. To support our on- 
going clinical protocols in allogeneic bone marrow transplantation, 
we have developed a fluorescence-based assay to monitor NIL func- 
tion that is accurate ven with limiting effector cell numbers. In this 
assay the target cells are labeled with carbo .xyfluorescein diaeetate suc- 
cinimydyl ester (CFSE). After incubations with NK cells, the kilting 
of target cells is monitored by their membrane permeability asdetect- 
ed with the nucleic acid stain 7-amino actinomycin D (TAAD). In par- 
allel assays, the CFSE-based assay generated dose-response curves 
similar to those achieved with SlCr release assays. However, the fluo- 
rescence-based assay remained sensitive at lower target cell numbers 
where the results of 51Cr-release assays were not interpretable. As 
would be anticipated, an immtmomagnetic selection of CD56 + ceils 
greatly increased the sensitivity of the assay. More importantly, with 
CD56+-selected ceils as effectors the CFSE-based lysis assay yields 
classic sig~oidal dose-response curves in assays performed in as little 
as one hour. Finally, we note that with this combination of fluores- 
cent dyes file samples can be fixed with formaldehyde and processed 
at a later time. Taken together, these data demonstrate his fluores- 
cence-based lysis assay issensitive, asy to conduct and time effective, 
yet the materials are inexpensive, making it suitable for clinical use. 
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NMDP MARROW COLLECTION CENTER EXPERIENCE AND ITS EFFECT 
ON CELL CONCENTRATION AND CELL DOSE 
Robit~ett, Pff. l; Simm; P. I; Hemlan, ft. 2; Karanes, C.1; Kelwalz, N.A. 3; 
Lymh, ff.p.4; Pvzepiorka, D. % Ubevti, ff /; Welte, IC ~ I. NMDP, Min- 
neapolis, 3/1N," 2. Thomas Jefferson U~ziversity Hospitals, Philadelphia, 
Rk 3. 3/lemorial Sloan Ketteri~zg Career Center, New York, NY," 
4. Saint Fmmis Hospital, Tul~:a, OK; 5. University of Tennessee, Mem- 
phis, TN," 6. University of Michigan Meckbal Ceme'r, Amz Arbor, 3/11. 
As increasing numbers of unrelated onor stem cell transplants 
utilize peripheral blood stem cells (PBSC), physicians are per- 
forming fewer marrow collections. The National Marrow Donor 
Program (NMDP) evaluated ata from its collection centers to 
determine if there were differences in marrow cellularity or donor 
morbidity based on the marrow collection experience of the col- 
lection center. NMDP collection centers (n=97) were divided into 
tbur groups, based on the nmnber of NMDP marrow collections 
performed at the center in 2001. Each group performed appro~ 
mately 25% of all NMDP marrow collections (n=926) in 2001. 
Group 1 centers each performed _>24 NMDP collections, group 2 
between 16 and 23, group 3 between 8 and 15 collections, and 
group 4 performed <7 collections in 2001. The median cell dose 
(x 10S/kg recipient weight) and median nucleated ceil concentra- 
tion (x 106/ml) were compared among groups using a median test. 
There was no significant difference in the median cell dose among 
the four groups of centers, however there was a borderline signifi- 
cant difference (P-value = 0.02) among median cell concentra- 
tions, where group 2 had a slightly higher median cell concentra- 
tion than the other groups. The incidence of severe (very intense, 
prolonged or excruciating) donor post-donation complication 
rates reported by NMDP donor centers was also compared. There 
were no significant differences among groups 1, 2, 3 and 4 at 
0.5%, 1%, 2% and 2% respectively. In conclusion, NMDP data 
do not appear to indicate that collection centers with less marrow 
collection experience produce less cellular products or result in 
increased onor morbidity. 
Group CentelS il  ~c~INM# of NMDP Median Cell p Valtle Median Cell 
Group Collections Do~c Concentration 
i 7 D e 12 :! 0,0 22~ 
I 229 4.1 244 
3 23 262 ] 36 220 
4 56 216 ] 4O 232 
P-Value 
002 
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FACTORS ASSOCIATED WITH AMBIVALENCE ABOUT BONE MAR- 
ROW DONATION AMONG NEWLY RECRUITED UNRELATED POTEN- 
TIAL DONORS 
Switze~% G.E.; Myaskovsky, L.; Goycoolea, J.M.; Dew, ~i. Medickze, 
University of Pittsbm-gh Medical Cemer, Pittsburgh, PA. 
Our previous research indicated that feelings of ambivalence or 
reluctance about donation were associated with donors' decisions 
not to donate, and with less positive physical and psychosocial 
outcomes among donors who donated espite feeling ambivalent. 
The current study examines the prevalence of ambivalence among 
newly recruited potential bone marrow donors, and identifies fac- 
tors associated with greater ambivalence. Using a cross-sectional 
design, questionnaires were mailed to a stratified random sample 
of individuals newly recruited to the NMDP registry at 71 local 
donor centers. 426 (63%) of new recruits completed and returned 
the questionnaire. Bivariate analyses indicated that multiple 
recruimmnt experience and donor perception variables were sig- 
nificantly associated with ambivalence. Multivariate analysis 
revealed that eight variables - -  participating in other volunteer 
activities (p<.05), joining at a drive for a specific patient (p<.05), 
perceiving the recruitment s aff as less informative (p<.001), being 
BB&MT 85 
